ANIP NASDAQ
ANI Pharmaceuticals, Inc.
1W: -2.5%
1M: -1.2%
3M: -15.1%
YTD: -8.0%
1Y: -20.0%
3Y: +19.8%
5Y: +125.9%
$72.18
-0.78 (-1.07%)
Weekly Expected Move ±4.3%
$66
$69
$72
$75
$78
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
21 relationships20
As Filer
counterparties named
1
As Counterparty
mentioned by others
4
Rel. Types
2021-11-26
Earliest Filing
2025-03-20
Latest Filing
partner: 9
target: 4
investor: 4
acquirer: 3
Counterparties (Filed by ANIP)
20 relationshipsCompanies named in ANIP's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Alimera Sciences, Inc. | ALIM | target | Target company acquired by ANI Pharmaceuticals, Inc. in a merger transaction. | 2024-09-20 | View |
| Continental Stock Transfer & Trust Company | — | partner | Rights Agent appointed to administer the Contingent Value Rights Agreement. | 2024-09-20 | View |
| Bank of Montreal | BERZ | partner | Option counterparty for capped call transactions | 2024-08-13 | View |
| Deutsche Bank AG | — | partner | Option counterparty for capped call transactions | 2024-08-13 | View |
| Mizuho Markets Americas LLC | — | partner | Option counterparty for capped call transactions | 2024-08-13 | View |
| Nomura Global Financial Products Inc. | NRSCF | partner | Option counterparty for capped call transactions | 2024-08-13 | View |
| Royal Bank of Canada | — | partner | Option counterparty for capped call transactions | 2024-08-13 | View |
| Alimera Sciences, Inc. | — | target | Target company in the pending acquisition financed by the new credit facility | 2024-08-13 | View |
| Alimera Sciences, Inc. | ALIM | target | Target company in the merger agreement with ANI Pharmaceuticals, Inc. | 2024-06-24 | View |
| ANI Pharmaceuticals, Inc. | ANIP | acquirer | Acquiring parent company entering into a merger agreement. | 2024-06-24 | View |
| Caligan Partners LP | — | investor | Investor entering into a voting agreement to support the merger. | 2024-06-24 | View |
| Caligan Partners Master Fund LP | — | investor | Investor entering into a voting agreement to support the merger. | 2024-06-24 | View |
| Caligan Partners CV VI LP | — | investor | Investor entering into a voting agreement to support the merger. | 2024-06-24 | View |
| 1540700 Ontario Limited | — | acquirer | Agreement to purchase ANI's Oakville, Ontario former manufacturing facility for $19.2M CAD. | 2024-02-23 | View |
| Novitium Pharma LLC | — | target | Target company acquired by ANI Pharmaceuticals, Inc. | 2021-11-26 | View |
| Nile Merger Sub LLC | — | acquirer | Wholly-owned subsidiary of ANI Pharmaceuticals, Inc. used to acquire Novitium. | 2021-11-26 | View |
| Esjay LLC | — | partner | Principal Member involved in the acquisition of Novitium. | 2021-11-26 | View |
| Chali Properties, LLC | — | partner | Principal Member involved in the acquisition of Novitium. | 2021-11-26 | View |
| Shareholder Representative Services LLC | — | partner | Representative of Company Members in the Merger Agreement. | 2021-11-26 | View |
| Ampersand 2020 Limited Partnership | — | investor | PIPE Investor providing equity funding for the acquisition. | 2021-11-26 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ANIP in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-24 | Officer/Director Change; Exhibits | View | |
| 2026-08-07 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-05-21 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-13 | Regulation FD; Exhibits | View | |
| 2026-05-08 | Earnings Release; Exhibits | View | |
| 2026-04-07 | Accountant Change; Exhibits | View | |
| 2026-03-03 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-01 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-26 | Unregistered Sales of Equity Securities; Material Modification to Rights of Security Holders | View | |
| 2025-09-08 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-29 | Other Events | View | |
| 2025-07-23 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-07-23 | Other Events; Financial Statements and Exhibits | View | |
| 2025-06-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-05-23 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR